Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome

Abstract

Objective The aim of the study is to perform a systematic review on the recent available evidence on antiphosphatidylserine/prothrombin (aPS/PT) antibodies and their association with clinical manifestations of the antiphospholipid syndrome (APS).

Methods A detailed literature search was applied a priori to Ovid MEDLINE, In-Process and Other Non-Indexed Citation 2012 to present and to abstract from EULAR and ACR/ARHP Annual Meetings (2012–2019).

Results Data from 2,901 patients, 587 diseases controls and 559 healthy controls included in 15 retrieved studies was analyzed. The patient population included 1,219 patients classified as APS according to the Sidney criteria, 285 patients with isolated persistently positive antiphospholipid antibodies (aPL) and 1,397 patients with a clinical suspicion of APS. Twelve studies, including 1,888 patients, analyzed the association between aPS/PT antibodies and thrombosis. We observed a statistically significant association between aPS/PT IgG/IgM positivity and thrombotic events (mean odds ratio [OR]: 6.8 [95% CI: 3.18–16.4], p < 0.05), confirmed when analyzing aPS/PT IgG (mean OR: 6.7 [95% CI: 3.04–21.6], p < 0.05) and aPS/PT IgM (mean OR: 4.35 [95% CI: 1.54–17.77], p < 0.05) separately. Seven studies, including 1,388 patients, evaluated the association between aPS/PT antibodies and PM. When pooled together, we found a statistically significant association between any PM and aPS/PT IgG/IgM positivity (mean OR: 10.6 [95% CI: 3.54–35.38], p < 0.05), particularly aPS/PT IgG positivity (mean OR: 6.7 [95% CI: 3.04–21.6], p < 0.05).

Conclusion Our results highlight the strong association between aPS/PT and the clinical manifestations of APS. With the available level of evidence, aPS/PT testing can be considered as a robust test applicable in the investigation of patients suspected for APS, also beyond the research settings.

Keywords

antiphospholipid syndrome - antiphospholipid antibodies - antiphosphatidylserine - antiphosphatidylserine/prothrombin - non criteria aPL - thrombosis - autoimmunity

Authors' Contributions

R.M., S.G.F., C.I., R.E., and S.K. searched the literature, assisted with the organization of the manuscript, interpreted and collected data, and wrote and edited the systematic review. R.M., S.S., R.D., and M.L.B. interpreted and collected data, helped to design the figures and panel, and wrote and edited the systematic review.

• References

• 1 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
• 2 Vikerfors A, Johansson A-B, Gustafsson JT. , et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays. Rheumatology (Oxford) 2013; 52 (03) 501-509
• 3 Pengo V, Biasiolo A, Bison E, Chantarangkul V, Tripodi A. ; Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res 2007; 120 (01) 127-133
• 4 Parkpian V, Verasertniyom O, Vanichapuntu M. , et al. Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome. Clin Rheumatol 2007; 26 (10) 1663-1670
• 5 Radin M, Cecchi I, Pérez-Sánchez C. Antiphospholipid antibodies negativization: time for testing for non-criteria aPL?. Lupus 2017; 26 (13) 1457-1458
• 6 Sciascia S, Radin M, Bazzan M, Roccatello D. Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Intern Emerg Med 2017; 12 (01) 1-7
• 7 Rodríguez-García V, Ioannou Y, Fernández-Nebro A, Isenberg DA, Giles IP. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology (Oxford) 2015; 54 (11) 2042-2050
• 8 Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology (Oxford) 2013; 52 (08) 1358-1367
• 9 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 2013; 52 (08) 1397-1403
• 10 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014; 111 (02) 354-364
• 11 Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011; 9: 1
• 12 PRISMA 2009 Checklist. Available at: http://prisma-statement.org/documents/PRISMA%202009%20checklist.pdf . Accessed February 11, 2020
• 13 Mullen MT, Messé SR, Kasner SE. , et al. Anti-phosphatidylserine-prothrombin antibodies are associated with outcome in aTIA cohort. Front Neurol 2012; 3: 1–6
• 14 Sciascia S, Sanna G, Murru V, Khamashta MA, Bertolaccini ML. Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. Thromb Res 2014; 133 (03) 451-454
• 15 Kim H, Kim JE, Hwang SM, Lee HR, Han KS, Kim HK. Synergistic thrombotic risk of antibodies against phosphatidylserine and prothrombin and β-2-glycoprotein I. Clin Appl Thromb Hemost 2014; 20 (04) 442-447
• 16 Hoxha A, Ruffatti A, Mattia E. , et al. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med 2015; 53 (08) 1265-1270
• 17 Žigon P, Perdan Pirkmajer K, Tomšič M. , et al. Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes. J Immunol Res 2015 Doi: 10.1155/2015/975704
• 18 Zuily S, de Laat B, Mohamed S. , et al; TAC(I)T investigators. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 2015; 54 (11) 2071-2075
• 19 Amengual O, Forastiero R, Sugiura-Ogasawara M. , et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus 2017; 26 (03) 266-276
• 20 Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost 2016; 14 (04) 675-684
• 21 Hoxha A, Mattia E, Tonello M, Grava C, Pengo V, Ruffatti A. Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med 2017; 55 (06) 890-898
• 22 Lee JS, Gu J, Park HS, Yoo HJ, Kim HK. Coexistence of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk. Clin Chem Lab Med 2017; 55 (06) 882-889
• 23 Zhu L, Li C, Liu N. , et al. Diagnostic value of antibodies to phosphatidylserine/prothrombin complex for antiphospholipid syndrome in Chinese patients. Clin Rheumatol 2017; 36 (02) 401-406
• 24 Zhang S, Wu Z, Zhang W. , et al. Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome. Clin Chem Lab Med 2018; 56 (06) 939-946
• 25 Shi H, Zheng H, Yin Y-F. , et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med 2018; 56 (04) 614-624
• 26 Ganapati A, Goel R, Kabeerdoss J, Gowri M, Mathew J, Danda D. Study of clinical utility of antibodies to phosphatidylserine/prothrombin complex in Asian-Indian patients with suspected APS. Clin Rheumatol 2019; 38 (02) 545-553
• 27 Núñez-Álvarez CA, Hernández-Molina G, Bermúdez-Bermejo P. , et al. Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome. Thromb Res 2019; 174: 141-147
• 28 Bertolaccini ML. Antibodies to prothrombin. Lupus 2012; 21 (07) 729-731
• 29 Pozzi N, Di Cera E. Prothrombin structure: unanticipated features and opportunities. Expert Rev Proteomics 2014; 11 (06) 653-655
• 30 Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005; 93 (02) 289-297
• 31 Bertolaccini ML, Gomez S, Pareja JFP. , et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64 (11) 1639-1643
• 32 Chinnaraj M, Planer W, Pengo V, Pozzi N. Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis. Blood Adv 2019; 3 (11) 1738-1749
• 33 Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 2012; 10 (12) 2512-2518
• 34 Pengo V, Del Ross T, Ruffatti A. , et al. Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. Thromb Res 2018; 172: 172-178
• 35 Tonello M, Mattia E, Favaro M. , et al. IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. Thromb Res 2019; 177: 157-160